Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons ...

With these new partnerships, Synergy has now established DSD coverage in ten of 50 U.S. states, representing one-fifth of the country within the first six weeks of launch. This milestone reflects the ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease ...

Inspire is scheduled to present at 11:30 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following ...

The gross proceeds to the Company from the Offering are estimated to be approximately $5.0 million before deducting the placement agent’s fees and other estimated Offering expenses. The Offering is ...

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop ...

According to the JV company agreement, Cuprina shall be responsible for implementing global sales strategies, marketing campaigns, and distribution networks for licensed products. Aiodine Laboratory ...

NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a strategic reseller partnership with 3DR Labs, LLC, one of the largest ...

The Phase 2 study is an open-label, fixed-sequence trial designed to evaluate the pharmacokinetic parameters and hemodynamic responses of NS002 compared to EpiPen in 50 healthy adults with a history ...

A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend ...

About NARCAN® Nasal Spray NARCAN ® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN ® Nasal ...